Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. … Read More
Repurposing Diabetes drugs for Alzheimer’s disease. View pathways associated with the action of Exenatide in Alzheimer’s.
Find Biomarkers and explore Pathways for Diabetes and Breast Cancer. Explore the live graph.